UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
TRUNCATE. Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis (TB): a randomised controlled non-inferiority trial
TB remains one of the most serious infectious diseases, causing high mortality and morbidity globally. Establishing effective short treatment regimens is a priority to combating the TB epidemic. The primary aim of this study is to determine whether a strategy of treating drug-sensitive TB for 2 months with one of a number of novel combination regimens and re-treating relapses with a 6 month course of standard treatment will be non-inferior to the standard 6 month treatment / 8-month re-treatment approach in terms of TB sputum culture status at 2 years after randomisation. The secondary aims are determining whether there are advantages of a 2 month initial treatment strategy for preventing the emergence of drug resistance, improving quality of life, and decreasing programme resource use and cost. The study also aims to determine the safety, tolerability and efficacy of a number of novel TB combination regimens.
4 Researchers
1 External Collaborators
  • Prof Nicholas Paton
    National University of Singapore - Singapore
 More search options
Status: Active
Topic-related Countries
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by